The SARS-CoV-2 pandemic has inflicted unprecedented mayhem on the healthcare systems and the global economies. Considering the emerging mutant strains of the virus and the subsequent waves of infections which has been hammering countries, there is an urgent need to develop novel antiviral drugs to effectively combat the menace. Significant efforts have been made to develop therapeutic interventions but still there are no approved drugs in the arsenal for this perilous disease.
Monoclonal antibodies (mAbs) that target a particular protein of the SARS-CoV-2 represent an attractive therapeutic option. They are laboratory-made proteins that mimic the ability of the immune system to ward off harmful stimuli such as viruses or bacteria. They can be cloned from B cell repertoire of recovered patients or genetically engineered in the laboratories. Despite being largest and fastest growing sector, production of monoclonal antibody (mAb) based therapeutics has limitations of time consuming and costly manufacturing process.
The development of single-chain variable fragments (scFv) antibodies (MW = ~ 33 kD) can be attractive alternative to full IgG mAbs (MW = 150 kD). The convalescent plasma from Covid survivors can be a rich source for isolation, amplification and cloning of anti-SARS-CoV-2 antibody genes for Antibody library building and ultimately Covid-19 neutralizing antibody screening & scFv production.
Techinvention has successfully generated two scFv libraries using phage display technologies from the convalescent plasma of Covid-19 recovered patients. The library includes one billion different clones of antibody genes (VHs-Vκs and VHs-VLs) with high probability to get high affinity fully human antibodies. This library will be used for the development of monoclonal antibody against multiple proteins of SARS-CoV-2 to address the issue of mutations.
The libraries can also be used for diagnostic purposes, bioassays kit development, affinity maturation, studying protein-protein interactions and developing antibodies against other viral diseases with grave consequences and unmet medical needs.
How we can help you
We offer our expertise and support to companies and organisations of all sizes as well as lifesciences investors and select academia. By working with us you will benefit from our incomparable domain knowledge and proven experience coupled with innovative strategies to ensure timely success for your initiative.